CBS 2019
CBSMD教育中心
English

推荐文献

科研文章

荐读文献

Percutaneous coronary intervention using a combination of robotics and telecommunications by an operator in a separate physical location from the patient: an early exploration into the feasibility of telestenting (the REMOTE-PCI study) Individualizing Revascularization Strategy for Diabetic Patients With Multivessel Coronary Disease A Novel Algorithm for Treating Chronic Total Coronary Artery Occlusion Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Multimodality imaging in cardiology: a statement on behalf of the Task Force on Multimodality Imaging of the European Association of Cardiovascular Imaging Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial Transcatheter Mitral-Valve Repair in Patients with Heart Failure 2019 ESC Guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC): Developed in collaboration with the Association for European Paediatric and Congenital Cardiology (AEPC)he management of patients with) Management of two major complications in the cardiac catheterisation laboratory: the no-reflow phenomenon and coronary perforations

Review ArticleVolume 70, Issue 17, October 2017, Pages 2171-2185

JOURNAL:J Am Coll Cardiol. Article Link

How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD

Hong KN, Fuster V, Bhatt DL et al. Keywords: cardiovascular disease; diabetes; hyperlipidemia; hypertension; primary prevention

ABSTRACT

Diabetes, hyperlipidemia, and hypertension are modifiable risk factors that predict cardiovascular disease events. The effect of these risk factors on incident cardiovascular disease increases with progressively higher levels of glucose, low-density lipoprotein cholesterol, and blood pressure. The thresholds for initiating treatment of these modifiable risk factors and the optimal goals of risk factor modification are a focus of primary prevention research. Although an aggressive approach is appealing, adverse events may occur, and potential physiological barriers may exist. This paper discusses primary prevention of coronary heart disease that may be achieved through modification of diabetes, hyperlipidemia, and hypertension by summarizing current guidelines and pertinent clinical trial data from intervention trials that included a primary prevention cohort.